This was a topic that was discussed during the workshop on neuropathology at the UK Research Collaborative conference in Newcastle a few weeks ago
From my MEA website report:
TUESDAY AFTERNOON: Research Workshops
Repeating the very successful format of the 2015 conference, delegates and speakers spent the afternoon by splitting into small groups that attended expert-led workshops. The workshops covered autonomic dysfunction (Dr James Frith, Newcastle University), clinical trials (Dr Esther Crawley, Bristol University), fatigue (Professor Julia Newton, Newcastle University), neuropathology (Richard Reynolds, Professor of Cellular Neuroscience, Imperial College, London), patient-reported outcome measures (Dr Kirstie Haywood, Warwick University).
Along with Professor Montoya, Professor Norman Booth, experts in neurology, neuropathology and neuroimaging, and two of the medical students the MEA sponsored to attend the conference, I attended a two hour neuropathology workshop.
Topics discussed included linking neuropathology to symptoms; the findings of dorsal root ganglionitis that have been reported from the UK post mortem research group; brain banking; lumbar punctures; are abnormalities in the brain focal or general?; and where do we go next in relation to investigating the neuropathology of ME/CFS with neuroimaging etc.
This group also briefly discussed the role of cytokine-mediated neuroinflammation and the new clinical trial involving a drug called anakinra that inhibits the pro-inflammatory cytokine IL-1. A member of the clinical trials group from The Netherlands had also joined this workshop.
Key reference:
Cytokine inhibition in ME/CFS – new clinical trial:
http://www.trialsjournal.com/content/16/1/439
So you might like to look at the info on the clinical trial
On a practical note in relation to ME/CFS, this is an approach to treatment that is well worth investigating (and there are other drugs that have been looked at) but this is not something that a doctor is going to prescribe (certainly here in the UK) to people with ME/CFS outside a research setting in our current state of knowledge